IA2030 – SP 1.3 Surveillance

Percent

Indicator selected for global monitoring for Immunization Agenda 2030 Strategic Priority Objective 1.3: Build and strengthen comprehensive vaccine-preventable disease surveillance as a component of the national public health surveillance system, supported by strong, reliable laboratory networks. WHO and UNICEF recommend that all districts (or appropriate country specific reporting level) report data in a timely manner for priority VPDs as outlined in WHO VPD surveillance standards. As these are new questions added to the WHO/UNICEF Joint Reporting Form on Immunization (JRF) for the Strategic Priority Indicator 1.3 and collating the data from district level upwards may pose some challenges, it was proposed that the questions of completeness and timeliness of reporting will be piloted in selected countries in all WHO regions in the reporting exercise for 2021 and 2022 data. The data from the pilot test year(s) will be assessed by a working group to explore capacity of countries to report on this IA-2030 indicator, improve reporting on this indicator, and finally, to identify where further work on surveillance reporting should be prioritized. Feedback from pilot countries on improvement of the questions or instructions will be reviewed.

Proportion of countries with complete and on-time reporting from 90% of districts for suspected cases of all priority VPDs included in nationwide surveillance Completeness: • Numerator: Total number of WHO Member States (or total number of pilot test countries for pilot test years) which reported having at least 90% of districts reporting for suspected cases of all priority VPDs included in nationwide surveillance • Denominator: Total number of WHO Member States (or total number of pilot test countries for pilot test years) Timeliness: • Numerator: Total number of WHO Member States (or total number of pilot test countries for pilot test years) which reported having at least 90% of districts reporting on-time for suspected cases of all priority VPDs included in nationwide surveillance • Denominator: Total number of WHO Member States (or total number of pilot test countries for pilot test years) Completeness and timeliness indicators are applicable for only those priority VPDs (as defined by the country) where the country surveillance system: (a) is nationwide (covering all districts or all appropriate country specific subnational jurisdictions (b) has stipulated a pre-defined frequency (or timeliness) or reporting, and (c) requires NIL reporting or zero reporting even when no cases have occurred from each district (or appropriate country specific reporting level) VPDs to be included: The list of VPDs should include polio and measles/rubella at a minimum for every country. Additional VPDs can be included by countries if they satisfy the three criteria above. • Baseline year: 2021

National Immunization Technical Advisory Group (NITAG) – A committee of recognized experts that provides technical advice and recommendations to the government regarding national immunization policies and programs. NITAG is a tool that enables the government to make evidence-based immunization policies through a transparent, systematic process. NITAGs are not regulatory, implementation or coordinating groups (such as Inter-agency Coordinating Committees or National Regulatory Authorities) and their primary function should focus on offering technical recommendations. As such, Inter-agency Coordinating Committees are NOT to be considered as NITAGs. Terms of References (TORs) – Documentation outlining the group’s purpose, serving also as a charter that outlines the group’s mode of functioning and code of practice for members. Conflict of Interest (COI) – To ensure transparency and avoid conflicts of interests as much as possible, NITAGs should require all members to declare their interests prior to official appointment. A conflict of interest (COI) occurs in the case of the member having a personal investment, activity, or relationship which may affect, or appear to affect, their responsibilities of the NITAG. A COI, whether real or perceived, can compromise the quality of the recommendations made by the group and can compromise the reputation and integrity of the NITAG. It can also compromise the credibility of the group, even if it would not influence the recommendations. Therefore, interests should be declared prior to the individual’s official appointment as a core member. The individual should only be appointed as a member if the person is considered an independent expert so that their interests do not compromise the integrity of the NITAG. Monitoring, Evaluation, and Action (ME&A) cycles –ME&A cycles for continuous quality improvement include the following steps: (1) Monitor: Measure and review key indicators on a routine basis defined by the country. Key indicators are measurable information used to determine if a program is implementing as expected and achieving its outcomes. Key indicators monitor performance of the national immunization program, could include any aspect of the immunization program (not limited to coverage indicators), and should be in alignment with the national immunization strategy or other strategic document. (2) Evaluate: Assess progress and identify areas for improvement (3) Act: For the areas for improvement identified, plan and implement actions to improve programmes.

WHO Member States (or total number of pilot test countries for pilot test years)

National immunization programme

Process

Step 1: Calculate the indicator numerator. • Completeness: Count the number of countries with at least 90% of districts reporting for suspected cases of all priority VPDs included in nationwide surveillance. o Countries to include in the numerator are identified by dividing the number of districts with at least 90% reporting for suspected cases of all priority VPDs included in nationwide surveillance by the total number of districts in the country. • Timeliness: Count the number of countries with at least 90% of districts reporting on-time for suspected cases of all priority VPDs included in nationwide surveillance. o Countries to include in the numerator are identified by dividing the number of districts with at least 90% on-time reporting for suspected cases of all priority VPDs included in nationwide surveillance by the total number of districts in the country. Step 2: Divide the indicator numerator by the total number of WHO Member States (denominator equals 194 WHO Member States). For pilot test years, the indicator numerator will be divided by the total number of pilot test countries instead. JRF Question used in indicator calculation: • What is the total number of 2nd / 3rd / 4th administrative level units in the country during {Year} (i.e., district, municipality)? • For the questions below, can you report on completeness and/or timeliness of VPD surveillance reporting by 3rd administrative level? • If no, can you report on completeness and/or timeliness of VPD surveillance reporting by 2nd administrative level or 4th administrative level? • Completeness: Number of administrative levels with at least 90% reporting for suspected cases of all priority VPDs included in nationwide surveillance • Timeliness: Number of administrative levels with at least 90% on-time reporting for suspected cases of all priority VPDs included in nationwide surveillance

Unweighted proportion

N/A

N/A

Annual

Annual

vpdata@who.int

7777

This is a VPD agnostic indicator and can work across disease specific systems of surveillance. Reported data is subject to numerous limitations. Country may not have submitted the data through the WHO/UNICEF Joint Reporting Form on Immunization (JRF) yet at the time of reporting. Complete and timely reporting has been a parameter for monitoring surveillance system performance over many years. However, as this indicator has not been collected at the global level systematically, it may take some time for the countries to establish a system to be able to report the data.